NASDAQ:TVGN Tevogen Bio (TVGN) Stock Price, News & Analysis $0.44 +0.01 (+2.33%) (As of 09/19/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrends Get Tevogen Bio alerts: Email Address About Tevogen Bio Stock (NASDAQ:TVGN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Tevogen Bio alerts:Sign Up Key Stats Today's Range$0.43▼$0.4850-Day Range$0.42▼$0.8052-Week Range$0.40▼$21.09Volume63,085 shsAverage Volume489,058 shsMarket Capitalization$73.09 millionP/E RatioN/ADividend YieldN/APrice Target$4.20Consensus RatingBuy Company OverviewTevogen Bio Holdings Inc. operates as a clinical-stage specialty immunotherapy company that develops off-the-shelf precision T cell therapies for the treatment of infectious diseases, cancers, and neurological disorders. The company develops TVGN 489, which has completed Phase 1 clinical trial for the treatment and prevention of chronic lingering symptoms of the disease (Long COVID), as well as COVID-19 in B cell immune suppressed acute COVID-19 patients without a B cell cancer indication, elderly and infirm acute COVID-19 patients, and acute COVID-19 in patients on T cell suppressing drugs, including solid organ transplant patients. It is also developing TVGN 601 for treating multiple sclerosis; TVGN 930 for the treatment of Epstein-Barr virus associated lymphomas; TVGN 920 for treating cervical cancer; and TVGN 960 for the treatment of mouth and throat cancer. The company was founded in 2020 and is headquartered in Warren, New Jersey.Read More… “I’ll Give You the Knowledge and Confidence You Need to Make Your First Options Trade in Five Days or Less… Guaranteed!” (Ad)Starting Monday, September 23 — a veteran 25-year Chicago Options Exchange market-maker will show you his UOA options secret that could help you consistently target gains of 126%… 245%… even 463% or more… Often in 30 days or less… No matter what the market is doing right now.Go here for the full details now. Tevogen Bio Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 81st PercentileTevogen Bio scored higher than 81% of companies evaluated by MarketBeat, and ranked 249th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingTevogen Bio has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageTevogen Bio has only been the subject of 1 research reports in the past 90 days.Read more about Tevogen Bio's stock forecast and price target. Earnings and ValuationN/AProj. Earnings GrowthN/A Short Interest5.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted3.09% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently decreased by 8.29%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldTevogen Bio does not currently pay a dividend.Dividend GrowthTevogen Bio does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted3.09% of the float of Tevogen Bio has been sold short.Short Interest Ratio / Days to CoverTevogen Bio has a short interest ratio ("days to cover") of 2.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Tevogen Bio has recently decreased by 8.29%, indicating that investor sentiment is improving significantly. News and Social Media2.0 / 5News SentimentN/A News SentimentTevogen Bio has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.44 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Tevogen Bio this week, compared to 2 articles on an average week.MarketBeat FollowsOnly 1 people have added Tevogen Bio to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.7 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Tevogen Bio insiders have not sold or bought any company stock.Percentage Held by Insiders56.60% of the stock of Tevogen Bio is held by insiders. A high percentage of insider ownership can be a sign of company health.Read more about Tevogen Bio's insider trading history. Receive TVGN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Tevogen Bio and its competitors with MarketBeat's FREE daily newsletter. Email Address TVGN Stock News HeadlinesTevogen Bio Holdings Inc.September 17 at 2:59 PM | wsj.comTevogen Bio Secures $6 Million Series C Preferred Stock InvestmentAugust 22, 2024 | markets.businessinsider.comThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start with diversification and experience. Founded in 2005, this company serves a diverse and expansive customer base with more than 8,000 retail locations, including licensed cannabis dispensaries, smoke shops, and specialty retailers. September 19, 2024 | Greenlane (Ad)Walmart Shares Jump on Q2 Earnings Beat, Guidance RaiseAugust 15, 2024 | au.finance.yahoo.comGap between Mag 7, rest of market is 'narrowing' in late 2024August 15, 2024 | uk.finance.yahoo.comCORRECTION – Tevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 15, 2024 | globenewswire.comTevogen Bio Reports Second Quarter 2024 Financial Results, Eliminates Doubt About Company's Ability to Continue as a Going Concern, Eliminates Series B Preferred SharesAugust 15, 2024 | globenewswire.comCheck out this $800 rotating VR chair for Meta QuestAugust 14, 2024 | au.finance.yahoo.comSee More Headlines TVGN Stock Analysis - Frequently Asked Questions How have TVGN shares performed this year? Tevogen Bio's stock was trading at $9.51 on January 1st, 2024. Since then, TVGN shares have decreased by 95.4% and is now trading at $0.44. View the best growth stocks for 2024 here. How do I buy shares of Tevogen Bio? Shares of TVGN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. Company Calendar Today9/19/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryN/A Current SymbolNASDAQ:TVGN Previous SymbolNASDAQ:TVGN CUSIPN/A CIK1860871 Webwww.semperparatusspac.com Phone913-579-4170FaxN/AEmployees17Year FoundedN/APrice Target and Rating Average Stock Price Target$4.20 High Stock Price Target$4.20 Low Stock Price Target$4.20 Potential Upside/Downside+854.5%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-70,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-387.78% Return on Assets434.75% Debt Debt-to-Equity RatioN/A Current Ratio0.23 Quick Ratio0.23 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value($1.10) per share Price / Book-0.40Miscellaneous Outstanding Shares166,114,000Free Float72,093,000Market Cap$73.09 million OptionableN/A Beta0.36 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report This page (NASDAQ:TVGN) was last updated on 9/19/2024 by MarketBeat.com Staff From Our PartnersSell NVDA Now?Guess who's selling NVDA next The most successful hedge fund in history quietly sold 500,000 shares. Here's...Chaikin Analytics | SponsoredThis diversified cannabis pioneer could make huge moves soonThe cannabis industry seems deeply saturated, so how do you know where to best invest your money? Let’s start ...Greenlane | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredProtect Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredThe death of Nvidia?Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S....Porter & Company | SponsoredForget ChatGPT: Follow the AI Retirement PlaybookEveryone’s talking about AI right now, but I’ve been talking about it for years. Follow this two-part playb...Brownstone Research | SponsoredDump Nvidia, Apple, and Tesla Before It’s Too LateThe financial world is on high alert. Billionaires like Warren Buffett, Jeff Bezos, and Elon Musk are dumpi...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Tevogen Bio Holdings Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Tevogen Bio With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.